

INDEX OF SUBJECTS

Abstracts, papers and (editorial), 1-2

Acetylcholine

- as defibrillating agent, 25, 26
- fibrillation induced by, 391-395
- peripheral blood after, 366

Ac-globulin

- platelet factor 1 differentiated from, 114
- in prothrombin activation, 515

ACTH, see Corticotropin

Acthar-Gel, 264

Actomyosin

- digitalis failing to affect, 226
- quantitative extraction of from dog myocardium, 215-219
 - and ATP sensitivity, 217-219, 223-224, 226-227
- spectrophotometric study of with drugs, 525-531
- Adenosine monophosphate (AMP)**, in experimental arteriopathies, 374-377
- Adenosine triphosphate (ATP)**
 - and "coronary chemoreflex" (v. Bezold-Jarisch effect), 372, 373
 - as defibrillating agent, 25-27
 - in experimental arteriopathies, 374-377
 - in generation of bioelectric potentials, 431
 - hypotensive action of, 371, 372
 - sensitivity of actomyosin, 217-219, 223-224, 226-227
 - spectrophotometric absorption of, 525-526, 529-530

Adrenalectomy

- bilateral, hypotensive action of, 461
- and ECG response of rat to ouabain, 281-283

Adrenalin, see Epinephrine

Albumin, iodinated serum

- cardiac output measured by, 564-568
- disappearance curve of, 15-17, 19-23
- indigo carmine curves compared with, 572, 573

Alcohol, ethyl, in pulmonary edema, 510-513

Ambonestyl, antiarrhythmic effects of, 335-342

- vs. procaine amide, 336, 338-341

American Heart Association

- awards, 645
- Basic Science Section, 119-120
- "Cardiac Clinics" (audio-visual kit), 316
- "Cardio-Views" (kit), 316
- "Cine-Angiograms for Teaching," 117
- Community Service and Education, Council on, 315-316
- "Congenital Heart Defects, Diagnosis of" (manual), 230
- "Diseases of the Heart and Blood Vessels" (manual), 230
- Gold heart awards, 646
- grants in aid, 229, 426
 - deadline, 316, 426, 544
- Halsey, R. H. (obit.), 647
- Heart Fund campaign, 117
- High Blood Pressure, Council for
 - meeting, 544
 - officers elected, 117-118
 - Proceedings volume, 544
- "Jones Criteria (modified) in Diagnosis of Rheumatic Fever," 646
- Jones, T. Duckett, Memorial Fund, 646
- "Prevention of Rheumatic Fever and Bacterial Endocarditis," restatement on, 229
- Registry of Cardiovascular Pathology, 544-545
- Scientific Sessions, New Orleans, 230, 315, 427, 543-544
- training program in cardiovascular research, 229
- work, exercise and heart disease, study of, 545

American Society for the Study of Arteriosclerosis, 118

Amino acids

- serum vs. connective tissue (rat), 521, 522, 523
- spectrophotometric identification of, 528

Ammonium chloride, in ventricular contraction recovery with glucose, 561-562

Anastomoses, interarterial coronary, role of anemia in, 307-310

Aneurysm, experimental "berry," jet action in, 463-467

Angiotonin, and vasoactivity, 122, 123

Anticoagulant(s)

- antiheparin activity of platelet factor 4, 113, 115
- antithrombin as, 401
 - with heparin, 402
- see also Heparin

Aortic strips, elasticity and damping of (dog), 403-408

Arrhythmias

- ambonestyl for, 335-342
- cyclopropane-epinephrine, drugs influencing, 291
- ouabain-induced, calcium and potassium in, 501, 504
- procaine amide for, 336, 338-341, 475, 476
- see also Fibrillation

Arterenal

- and blood volume, "central," of dog, 385-389
- in meningococci hypotension, 380-381
- and vasoactivity, 122, 123, 125, 127-128

Arteriosclerosis

- American Society for Study of, 118
- epinephrine-thyroxine induced, ATP, AMP and heparin in, 374-377
- Minnesota symposium on, 427-428
- pulmonary
 - histopathology of, 154
 - related to blood flow and pressure, 152, 154-158

Ascites, hypophysectomy and electrolyte influence on formation of, 270-272

Atherogenesis, tissue permeability in, cortisone and hyaluronidase effects on, 293-295

Atherosclerosis

- cholesterol-induced
 - ATP, AMP and heparin in, 374-377
 - phosphatidyl choline formation capacity in, 49
- experimental canine, protein-lipid relations in, 199-201
- ovariectomy effects on, 191-192

Atrium, membrane potentials and contractility of rat, 604-611

Atropine

- blockade, vasoactivity affected by, 176-177
- as defibrillatory agent, 393, 395

Awards, see American Heart Association; Grants

Bacterial endocarditis, prevention of, A.H.A. statement on, 229

v. Bezold-Jarisch effect, drugs eliciting, 363, 372, 373

Bioelectric potentials, generation of, 429-433

Blakeslee Award, 647

Bleeding technic, ultra-rapid, arterial pressure-volume relations studied by, 86-93

Blood, peripheral

- postsurgical, 287-288
- and splanchnic discharge after acetylcholine, 366

Blood coagulation, platelet factor functions in, 110-115, 515, 516

Blood flow

- cerebral, thorium B labeling for study of, 79-84

- electromagnetic flowmeter for measuring, 39-45
 hepatic, in hemorrhage, 68
 BSP determinations, 67
 peripheral, limb posture changes affecting, 478-482
 pulmonary
 related to pulmonary arteriosclerosis, 154-158
 respiratory role in, 210-213
 reactive hyperemia, 582-586
 resistance to, intraluminal pressure influences on, 358-361
- Blood pressure**
 arterial
 in hemorrhage, 66-67
 in moderator reflexes elimination, 416-420
 pressure pulses simultaneously recorded, 623-631
 and renal hemodynamic function in heart failure, 254-257
 Digoxin in, 259-262
 volume relationships, in rapid bleeding technic, 86-93
 atrial
 in dinitrophenol poisoning, 35
 pericardial effect on, 134-138
 cardiac output determinations correlated with Evans blue method, 506-509
 coronary artery, decreased, and right ventricular weakening, 633-637
 flow resistance related to, 358-361
 high, A.H.A. Council for, 117-118, 544
 see also Hypertension
 hypophysectomy plus hormones influencing, 268-269
 intra-arterial, and reactive hyperemia blood flow, 583-585
 low, *see* Hypotension
 meningococcus toxin effect on, 378-383
 pulmonary artery, related to pulmonary arteriosclerosis, 154-158
 and splanchnic activity, 364-367
 hypotensive drugs, 368-373
 ventricular, right, inotropic drug effects on, 448
 wedge
 pulmonary arterial and venous related, 3-6
 pulmonary vein vs. pulmonary venous and atrial pressures, 7-11
- Blood volume**
 carcass vs. visceral, 487-488
 "central," of dog, 1-arterenol in, 385-388
 of leg, human, 486-487
 meningococcus toxin effect on, 380
- Book reviews**
 Ciba Foundation Symposium on Hypertension (Wolstenholme and Cameron), 116
 Congenital Heart Disease (Abbott), 425
 Shock and Circulatory Homeostasis (Green), 425
 Travaux de L'Institut de Recherches Cardiologiques de Royat (Jourdan), 116
 Verhandlungen der Deutschen Gesellschaft für Kreislaufforschung, 425
- Calcium**
 as defibrillating agent, 25, 26
 -induced fibrillation, antiarrhythmic agents vs., 474-476
 ouabain-induced arrhythmias affected by, 501-504
 ECG of, 276-278
 serum, in hypothermic fibrillation, 576-578
- Capillary permeability**, to dextran macromolecules, 594-603
- Cardiac arrest**, hypothermic, oxygen effect on, 28-31
- Cardiac output**
 colorimeter for dye method determinations of, 470-471
 hypophysectomy plus hormones influencing, 268-269
 measured by iodinated serum albumin, 564-568
 meningococcus toxin effect on, 379-380
 in moderator reflexes elimination, 416-420
 in pregnancy, Evans blue and blood pressure methods correlated, 506-509
- Cardiac work**, ventricular filling affected by, 436-445
- Cardiac**, *see also* Heart
- Chloride**, serum, in hypothermic fibrillation, 576
- Cholesterol**, dietary
 in atherogenesis, 293-295
 phosphatidyl choline formation stimulated by, 47-49
- Cholesterol**, serum
 vs. connective tissue, 345-349, 520-522
 heparinized, phosphatide and lecithin influence on disappearance of, 166-169
- Cholesterolemia**, hyper-, in ovariectomy, 191-192
- Cholic acid**, in cholesterol metabolism, 48-49
- Choline deficiency**, lipoproteins in, 549-551
- Cholinesterase**, anti-, agents, and fibrillations, 391-393
- Cohn's microfractionation method 10**, plasma protein-lipid relationships determined by, 194-198
- Collateral circulation to lung**, after pulmonary artery occlusion, 422-423
- Colorimeter**, whole blood, for continuous registration of Evans blue concentration, 469-472
- Compound F hypertension**, salt load test in, 302-303
- Congenital heart defects**
 A.H.A. manual on, 230
 Atlas of (book review), 425
- Cooling**, *see* Hypothermia
- "Coronary chemoreflex"** (v. Bezold-Jarisch effect), drugs eliciting, 363, 372, 373
- Coronary perfusion arrest**, for defibrillation, 24
- Corticotropin (ACTH)**
 in electrolyte excretion after hypophysectomy, 267-272
 for myocardial infarction, 496-500
- Cortisone**
 in altitude endocarditis, 353
 vs. atherosclerosis, 293-295
 in meningococci hypotension, 381-382
 for myocardial infarction, 499
- Cyclopropane-epinephrine arrhythmias**, drugs influencing, 291
- Denervation**, arterial diameter and reactivity after, 618-621
- Desoxycorticosterone acetate (DCA)**
 and electrolyte excretion, 267-272
 hypertension, salt load test in, 301-302
 and ouabain response of rat, 281-283
- Dextran**, capillary permeability to macromolecules of, 594-603
- Dibenamine**, hypotensive action of, 460
- Diet**, in hypertension, experimental, 73-76
 and periarteritis nodosa, 76-77
- β -Diethylaminoethyl diphenylpropylacetate hydrochloride**, in cyclopropane-epinephrine arrhythmias, 291
- Digitalis**, actomyosin unaffected by, 226
- Digitoxin**, spectrophotometric absorption of, 527, 530
- Dinitrophenol (DNP)**, heart-lung function and O₂ uptake in poisoning of, 32-37
- Diphenylhydantoin sodium**, in cyclopropane-epinephrine arrhythmias, 291
- Electric defibrillation**, 25, 26
- Electrocardiogram**
 ambonestyl and procaine amide effects on, 338, 339
 and calcium effect on ouabainized heart, 276-278

in ectopic beats, 541
and epinephrine effect on ouabainized heart, 274-275, 277-278
finite boundaries, effect of, 233, 236
electrolytic tank for plotting, 236-239
images for solution of problems of, 239-241
in interventricular septum excitation, 57-58, 62-63
of normal rat, 281
in ouabain-induced arrhythmias, 502-504
QRS complex
in ouabainized heart, 275-278
and speed of ventricular activation, 409-414
QRS equipotentials, comparison of, 243-250
Electrocardiography
research in (editorial), 231-235
spatial vectors, comparative measurements of, 320-328
Electrolytes
hypophysectomy effect on excretion of in vena cava constriction, 266-272
in hypothermic ventricular fibrillation, 575-578
Electrolytic tank, for field plotting, 236-237
applications of, 237-239
Electromagnetic flowmeter, square wave, for intact blood vessels, 39-45
Endocarditis susceptibility, and polycythemia, 352-355
cortisone in, 353
Epinephrine (adrenalin)
arterial response to after denervation, 618-621
-cyclopropane arrhythmias, drugs influencing, 291
inhibitor-potential, in rat mesoappendix bioassay, 121-132
vs. inotropic drugs in ventricular filling, 450-451
myocardial avidity for, 553-558
in ouabainized heart, ECG of, 274-275, 277-278
and vasoactivity, 172-178
and ventricular vulnerability, 142-145
Estrogens, in cholesterol-induced coronary atherosclerosis, 191-192
"et al." (editorial), 547-548
Ether, diethyl, ventricular filling affect by, 449, 450
Ferritin, and vasoactivity, 122, 123, 125, 127, 129-131
Fibrillation
atropine vs., 393, 395
auricular, acetylcholine-induced, 391-395
calcium-induced, antiarrhythmic agents in, 474-476
hypothermic ventricular, electrolytes in, 576-578
ventricular
defibrillating agents, comparison of, 24-27
defibrillation effects of ventricular vulnerability, 150-151
thresholds, relation between ventricular resting excitability and, 143-145
see also Arrhythmias
Filling, right ventricular
inotropic drug effects on, 448-452
work load and heart rate effects on, 436-445
Fourneau 933, hypotensive action of, 460
Freon, in pulmonary edema
Glomerular filtration rate (GFR)
hypophysectomy effect on, 269
in right heart failure, 254-257
Digoxin effect on, 260-262
Glucose, in cyclopropane-epinephrine arrhythmias, 291
Glutathione, and vasoactivity, 123, 125
Gold, radioactive colloidal (Au¹⁹⁸), disappearance of from circulating blood, method for continuously recording, 14-15, 17-18

Gordon Research Conference on Blood, 229-230
Grants
American Heart Association, 229, 426, 544
Life Insurance Medical Research Fund, 544
Heart
-lung, mechanical, 150-164
muscle, *see* Myocardium
temperature effects on, 24-27
work capacity of, dinitrophenol effect on, 33, 35
see also Cardiac
Heart failure
actomyosin in, 221-227
dinitrophenol, function and O₂ uptake in, 32-37
right, by progressive pulmonary artery constriction, 252-257
Digoxin in, 259-262
Heart Fund campaign, 117
Heart rate
in dinitrophenol poisoning, 35
ventricular filling affected by, 439-445
Heart sound, third, pericardial tensing in, 51-54
characteristics of, 54
Heart volume, in dinitrophenol poisoning, 35
Hemorrhage
arterial pressure in, 66-67
hepatic blood flow in, 68
BSP determinations, 67
hepatic blood O₂ saturation in shock of, 312-314
kidney, in choline deficiency, 550
O₂ uptake, splanchnic, in, 68-70
vs. total consumption, 70
venomotor tone in, 186
Heparin
cofactor in plasma fractions, 400-401
in experimental arteriopathies, 375, 376
with serum cholesterol, lecithin and phosphatide affecting, 166-169
Hepatic, *see* Liver
Hexamethonium, vs. strophanthin-K, 107
Histamine
-like "H-substance," in reactive hyperemia, 585
and vasoactivity, 122, 123, 129
Hyaluronidase, vs. cortisone in atherogenesis, 294-295
Hydergine, hypotensive action of, 460-461
Hydrogen ion, in hypothermic fibrillation, 576-578
Hyperemia, reactive, mechanism of, 581-586
Hypertension
arterial, hemidecortication causing, 450-460
treatment of, 460-461
ATP in, 371, 372
book review, 116
diet in experimental, 73-76
and periarteritis nodosa, 76-77
protoveratrin in, 368-369, 371-372
serotonin in, 369-370, 371-372
sodium tolerance in, 297-304, 490
Pitressin effect on, 491-495
see also Blood pressure
Hyperthermia, and atrial membrane potential and contractility, 600-610
Hypoadrenalism, and ouabain response of rat, 281-283
Hypocalcemia-hypokalemia-ouabain, interrelated cardiac effects of, 501-504
Hypophysectomy, electrolyte excretion affected by, 266-272
Hypotension
hemorrhagic
splanchnic activity in, 365
venomotor tone in, 186
meningococci, 378-383
see also Blood pressure

Hypothermia

- with dinitrophenol poisoning, O_2 uptake in, 35-36
- of heart
 - for defibrillation, 24-27
 - O_2 effect on cardiac arrest of, 28-31
- ventricular fibrillation of, electrolytes and pH in, 575-578

Indigo carmine, for dye dilution curves, 570-573**Infarct**, *see* Myocardial infarction**Interventricular septum**, excitation of, multipolar recording of, 56-64**Iodine, radio- (I^{131})**

- disappearance of from circulating blood, method for continuously recording, 14-17, 19-23
- serum albumin
 - cardiac output measured by, 564-568
 - indigo carmine curves compared with, 572, 573
 - validating experiments for use of, 483-486

Kidney

- function
 - hemodynamic, in heart failure, 254-256
 - Digoxin in, 259-262
 - hypophysectomy plus hormones in, 268-269
- hemorrhage, in choline deficiency, 550
- hypertension, salt load test in, 300-301
- VEM preparation, and vasoactivity, 122, 123, 125, 126, 128

Lanatoside C, in dinitrophenol poisoning, 32-37**Lasker Award**, 647**Lecithin**, in disappearance of incubated serum cholesterol, 167-169**Life Insurance Medical Research Fund**, award deadlines, 544**Lipid(s)**

- protein relationships
 - in atherosclerosis, 199-201
 - in dog plasma, normal, Cohn's method 10 determining, 194-198
- serum vs. connective tissue, 344-349, 519-523

Lipoproteins, in choline deficiency, 549-551**Liver**

- O_2 saturation in hemorrhagic shock, 312-314
- VDM preparation, and vasoactivity, 122, 123, 124

Lynadryl, with platelet factor 3, prothrombin activation by, 113**Magnesium**, serum, in hypothermic fibrillation, 576**Malonate**, in ventricular contraction recovery with glucose, 560-561**Marrow**, and postsurgical thrombocytopoiesis, 287-289**Mecholyl**, and vasoactivity, 125**Meningococcus toxin**, hypotension of, 378-383**Muscle**

- heart, *see* Myocardium
- VDM preparation, and vasoactivity, 123

Myocardial infarction

- ACTH effect on, 496-500
- cortisone effect on, 499
- experimental production of standard predictable, 496-497, 499

Myocardium

- actomyosin quantitative extraction from, 215-219
- and ATP sensitivity, 217-219
- depolarization and repolarization of determined by spatial vectorcardiography, 203-209
- epinephrine and norepinephrine avidity of, 553-558
- protein composition of, normal vs. chronic heart failure, 222-227

Norepinephrine

- myocardial avidity for, 553-558
- and vasoactivity, 172-178
- and ventricular vulnerability, 142-145

Optical density ratios, 529-530**Ouabain arrhythmias**, calcium and potassium effects on, 501-504**Ouabainized heart**

- adrenalectomy effect on, 281-283
- DCA effect on, 281-283
- epinephrine and calcium effect on ECG of, 274-278

Ovarietomy, and atherosclerosis, 191-192**Oxygen**

- in hypothermic cardiac arrest, 28-31
- saturation
 - colorimeter correction for in cardiac output determinations, 471
 - of hepatic blood in hemorrhagic shock, 312-314
 - with mechanical heart-lung, 162
 - of pulmonary vein wedge samples, 11
- uptake, cardiac, in dinitrophenol poisoning, 32-37
- with hypothermia, 35-36
- uptake, splanchnic, in hemorrhage, 68-70
- vs. total, 70

Patent ductus arteriosus, hydraulics in simulated, 613-617**Pericardium**, in cardiovascular hemodynamics, role of, 133-138**pH, blood**, in hypothermic fibrillation, 576-578**Phenoxybenzamine**, vasoactivity in adrenergic blockade with, 175**Phosphatide**, in disappearance of incubated serum cholesterol, 166-169**Phosphatidyl choline**, cholesterol stimulating formation of, 47-49**Phosphorus, radio- (P^{32})**, disappearance of from circulating blood, method for continuously recording, 14-15, 17**Pitressin**

- hypertensive sodium tolerance affected by, 491-495
- and vasoactivity, 123, 125, 129

Platelets

- factors of, specific properties of in coagulation, 110-115, 515, 516
- postsurgical, 287-288

Polyarteritis nodosa, etiology of rat, 76-77**Polycythemia**, and endocarditis susceptibility, 352-355**Posture, limb**, peripheral blood flow affected by, 478-482**Potassium**

- as defibrillating agent, 25, 26
- ouabain-induced arrhythmias affected by, 501-504
- radioactive (K^{43}), disappearance of from circulating blood, method for continuously recording, 14-15, 17-18
- serum, in hypothermic fibrillation, 576-578

Pregnancy, cardiac output in, 506-509**Pressures**, *see* Blood pressure**Procaine amide**

- antiarrhythmic effects compared with ambonestyl, 336, 338-341
- in calcium-induced arrhythmias, 475, 476
- dangers of, after cardiac glycosides, 108
- vs. strophanthin-K, 106-107

Protein

- lipid relationships
 - in atherosclerosis, 199-201
 - in plasma, Cohn's method 10 determining, 194-198
- myocardial, normal vs. chronic heart failure, 222-227

- quantitative determination of in heart, 454-457
- serum vs. connective tissue, 520, 522
- Prothrombin**
 - activation
 - by platelet factor 1, 111-112
 - by platelet factor 3 with Lynadryl, 113
 - thrombin in, 113
 - serum, conversion accelerator (SPCA) plasma, coagulation mechanism in, 514-517
- Protoveratrine**, hypotensive action of, 368-369, 371-372
- Pulmonary edema**, antifoaming agents in, 510-513
- Pulmonic stenosis**, right heart failure studies in, 256-257
- Quinidine**
 - in calcium-induced arrhythmias, 475, 476
 - dangers of, after cardiac glycosides, 108
 - vs. strophanthin-K, 103-106
- Radioactive tracers**, *see specific elements*
- Rat mesoappendix bioassay**, as vasoactivity indicator, 121-132
- Registry of Cardiovascular Pathology**, 544-545
- Regurgitation**, ventriculo-atrial, pericardium preventing, 136
- Renal**, *see Kidney*
- Renin**, and vasoactivity, 123, 125, 128
- Research**
 - in electrocardiography (editorial), 231-235
 - prelude to (editorial), 317-319
- Respiration**, role of in pulmonary blood flow and venous return, 210-213
- Rheumatic fever**
 - "Jones Criteria (Modifieu) for Guidance in Diagnosis of," 646
 - prevention of, A.H.A. statement on, 229
- Sarin**, as anticholinesterase agent, 390, 391, 392
- SC-2919**, -3323, -3412, -3755, -3920, in calcium-induced arrhythmias, 475-476
- Serotonin**, hypotensive action of, 369-370, 371-372
- Shock**
 - and circulatory homeostasis (book review), 425
 - hemorrhagic, *see Hemorrhage*
 - of meningococic hypotension, 378-383
 - normovolemic, venomotor tone in, 186-187
- Silicone aerosol**, in pulmonary edema, 510-513
- Sodium**
 - excretion, hypophysectomy plus hormones influencing, 266-269, 271-272
 - pentobarbital, ventricular filling affected by, 449, 450-451
 - radio- (Na^{22}), total tissue sodium determined by, 330-333
 - radio- (Na^{24}), disappearance from circulating blood, method for continuously recording, 14-15, 17
 - retention, in heart failure, 254-256
 - Digoxin in, 259-262
 - serum, in hypothermic fibrillation, 576
 - thiopental, ventricular filling affected by, 449, 450-451
 - tolerance, in hypertension, 297-304, 490
 - Pitressin effect on, 491-495
 - total tissue determination, 330-333
- SPCA**, *see Prothrombin*
- Splanchnic nerve activity**, blood pressure and, 364-367
 - hypotensive drugs in, 368-373
- Stereovector electrocardiograph (SVEC)**
 - spatial ECG vectors measured by, 320-328
- speed of ventricular activation measured by, 409-414
- Strophanthin-K**
 - vs. hexamethonium, 107
 - vs. inotropic drugs in ventricular filling, 449-451
 - vs. procaine amide, 106-107
 - vs. quinidine, 103-106
- Surgery**
 - Cardiovascular, International Symposium on, 118
 - and thrombocytogenesis, 285, 287-289
- Sympathectomy**, limb posture changes affecting blood flow in, 481
- Sympathin**, *see Epinephrine; Norepinephrine*
- Systoles**, premature ventricular, excitation spread during, 535-541
- Tabun**, as anticholinesterase agent, 390, 391, 392, 393
- Temperature**, heart, and fibrillation, 24-27
 - see also Hypothermia*
- Tetraethylammonium bromide**, hypotensive action of, 460
- Thorium B**, cerebral blood flow studied by labeled, 79-84
- Threone activity**, platelet factor 3 in, 114
- Thrombin**, anti-
 - as anticoagulant, 401
 - measurement of, 398-399
 - preparation of concentrates, 399-400
 - see also Prothrombin*
- Thrombocytogenesis**, after surgery, 285, 287-289
- Vasoactivity**
 - rat mesoappendix bioassay of with biologic materials, 122-132
 - terminology of, new, 121
- Vectorcardiography**
 - different results from different leads in, significance of, 532-534
 - myocardial depolarization and repolarization determined by, 203-209
 - spatial vectors, comparative measurements of, 320-328
 - see also Stereovector electrocardiograph; Zero of potential*
- Vena cava**, thoracic inferior, constriction of, ascites production and electrolyte excretion in, 264-272
- Venomotor tone**, in hemorrhage and shock, 181-189
- Venous return**, respiratory role in, 210-213
- Ventricle**
 - contraction of, energy sources for, 559-563
 - function, pericardial effects on, 135
 - length-circumference relations of left, 639-643
 - strength of right dependent on coronary artery pressure, 633-637
 - volume curves, left, method for recording, 588-593
 - vulnerability, 141-146, 147-149
 - defibrillation effects on, 150-151
 - epinephrine and norepinephrine effects on, 142-145
 - wall of, properties during filling, 443
 - with inotropic drugs, 451-452
 - see also Filling*
- Veratridine**, spectrophotometric absorption of, 527-528, 530
- Weber's solution**, 215
- World Congress of Cardiology**, Third (1958), 647
- Zero of potential**, adjusting Wilson central terminal to in human, 94-101